Basaglar Kwikpen Injectable
Basaglar Kwikpen is an FDA-approved preparation containing Basaglar Kwikpen, for veterinary use. Available by prescription.
Giving your pet an injection might feel intimidating at first, but with practice, it becomes routine. Follow these steps for safe and stress-free injections.
Get Your Supplies Ready
- Medication vial or pre-filled syringe
- Alcohol swabs
- Sterile syringe & needle (if not pre-filled)
- Sharps container for safe needle disposal
Drawing Up the Dose (if needed)
- Clean the vial top with an alcohol swab
- Attach needle to syringe
- Pull in air equal to the dose
- Insert needle into vial, push air in
- Draw out the correct dose
- Tap out air bubbles
Pick the Injection Site
- Subcutaneous (under the skin): Loose skin between shoulder blades or side
- Intramuscular (into muscle): As directed by your vet
Prep the Area
- Pinch a fold of skin to form a “tent” (for subcutaneous). Wipe with alcohol if recommended.
Inject the Medication
- Hold the syringe like a pencil
- Insert the needle into the base of the skin tent at a 45° angle
- Push the plunger slowly to inject
After the Injection
- Remove the needle smoothly
- Place it immediately in the sharps container (don’t recap)
- Pat the area and give your pet praise or a treat
Safety Tips
- Never reuse needles
- Always dispose of used needles properly
- Ask your vet for help if unsure
Veterinarians most commonly consider insulin glargine, available as Basaglar, in the context of feline diabetes mellitus, though it is also discussed for canine patients. It is frequently a point of discussion for endocrine health protocols because of its extended duration of action. The KwikPen delivery system offers a specialized method of administration that allows for precise, dial-a-dose increments, which your veterinarian may find useful for the specific metabolic requirements of your pet.
At a pharmacological level, insulin glargine is produced by recombinant DNA technology and differs from natural human insulin by the substitution of the amino acid glycine at position A21 and the addition of two arginines at the C-terminus of the B-chain. These modifications shift the isoelectric point, making the molecule less soluble at a neutral pH. Once administered into the subcutaneous tissue, the acidic solution is neutralized, leading to the formation of microprecipitates. These precipitates allow for the slow, steady release of insulin into the bloodstream over a 24 hour period. This mechanism provides a relatively constant concentration of insulin without the pronounced peaks and troughs associated with other formulations. Your veterinarian will determine whether this medication is appropriate based on your pet's blood glucose curves and clinical response.
The actions described here reflect the product's FDA-approved labeling; your veterinarian determines the appropriate use for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring.
Commonly observed effects following the administration of insulin include hypoglycemia (low blood sugar), which is a significant clinical consideration for any diabetic patient. Observational signs of hypoglycemia may include lethargy, weakness, stumbling, head tilting or, in severe cases, seizures. Owners should watch for any behavioral shifts following an injection and contact their veterinarian promptly if these occur. Additionally, localized skin reactions or changes in the fat tissue at the injection site (lipodystrophy) may be noted if administration sites are not rotated as directed by a professional.
This medication is typically used with extra caution or avoided in pets during episodes of diabetic ketoacidosis or in those with a known hypersensitivity to insulin glargine. Because insulin requirements can shift based on diet, activity levels and concurrent health challenges like infectious diseases, frequent monitoring of blood or urine glucose is essential. Before starting a protocol, ensure your veterinarian has a complete history of all other prescriptions your pet is receiving, as certain medications can influence insulin sensitivity. Your veterinarian is the right person to provide guidance on the necessary monitoring schedule and the proper storage and handling of the KwikPen to maintain the stability of the insulin.
Yes. Basaglar KwikPen is a prescription insulin medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all authorizations before any medication is shipped to your home.
Basaglar KwikPen is a proprietary commercial insulin glargine delivery system manufactured to maintain specific pH and stability standards. While Mixlab compounds many medications, insulin glargine is dispensed in its original commercial pen or vial format to ensure the integrity of the long-acting insulin crystals as intended by the manufacturer.
Basaglar and Lantus both contain the same active ingredient, insulin glargine and are considered biologically similar. Veterinarians may discuss Basaglar as a relevant option for managing glucose levels, as it follows the same peakless mechanism of action, though any switch between brands should only be performed under the direct guidance of a professional.
Unopened Basaglar KwikPens should be kept in the refrigerator until they are ready for use. Once a pen is in use, your veterinarian will provide specific guidance on whether to keep it at room temperature or refrigerated, though it must always be kept away from direct heat and light to maintain the effectiveness of the insulin.
